In addition, by cooperating with ErbB2, a loss of Par3 can inhibit the junction stability of E-cadherin and disrupt cell–cell junctions and cell–cell cohesion through the Tiam1/Rac-GTP pathway, resulting in accelerated metastasis of breast cancer in vivo. Here, PARD3 is linked to breast carcinoma.